Quick Takeaways
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 24 Feb 2022, 19:17.
Robert E. Waltermire - 24 Feb 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Signature
- /s/ Brian J. Lynch, As attorney-in-fact for Reporting Person
- Issuer symbol
- MDGL
- Transactions as of
- 24 Feb 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 24 Feb 2022, 19:17:26 UTC
- Previous filing
- 04 Aug 2021
- Next filing
- 18 Jan 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 24 Feb 2022."
What Changed
- Previous filing in this sequence was filed on 04 Aug 2021.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDGL | Call Option | Award | $0 | +12,250 | $0.000000 | 12,250 | 24 Feb 2022 | Common Stock | 12,250 | $87.09 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option vests as to 25% of the shares on the first anniversary of the date of grant (02/24/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |